China NMPA Drug Inspection - Marketing Authorization Holder: Shenzhen Jiurui Health Technology Development Co., Ltd.; Trustee: Sinopharm Group Guangdong Global Pharmaceutical Co., Ltd. - Nifedipine Extended-Release Tablets
China NMPA drug inspection for Marketing Authorization Holder: Shenzhen Jiurui Health Technology Development Co., Ltd.; Trustee: Sinopharm Group Guangdong Global Pharmaceutical Co., Ltd. published December 01, 2017. Drug: Nifedipine Extended-Release Tablets. This document, the "Ningxia Drug Quality Sampling Inspection Information Announcement (No. 14, 2017)," was published by
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Marketing Authorization Holder: Shenzhen Jiurui Health Technology Development Co., Ltd.; Trustee: Sinopharm Group Guangdong Global Pharmaceutical Co., Ltd. published December 01, 2017. Drug: Nifedipine Extended-Release Tablets. This document, the "Ningxia Drug Quality Sampling Inspection Information Announcement (No. 14, 2017)," was published by
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox